Oslo, Norway, 10 September 2025 - Zelluna (OSE: ZLNA), a company pioneering
allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells
for the treatment of cancer, announces an Investor Science and Strategy Forum to
be held in Oslo on Wednesday 17 September 2025 at 11:30am CET.

Attendance by registration only.

The format will be a panel discussion and open questions and answers (Q&A).

The panel will include:

Dr. Namir Hassan, CEO, Zelluna ASA, Moderator

Prof. Bent Jakobsen, Pioneer of T Cell Receptor (TCR) therapy for cancer